To date, one phase 1 clinical trial (NCT03392064) has been conducted using AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3 for the treatment of relapsed/refractory SCLC patients [101]. The gene discussed is DLL3; the disease is small cell lung carcinoma.